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Abstract: In recent years, many experiments have been conducted for the production and evalu-
ation of anticancer glycoconjugated vaccines in developed countries and many achievements 
have been accomplished with Globo H derivatives. In the current experiment, a new chemically 
designed triplicate version of (Globo H)
3
–diethylenetriamine pentaacetic acid (DTPA)–KLH 
antigen was synthesized and characterized. Immunization with (Globo H)
3
-DTPA-KLH, a 
hexasaccharide that is a member of a family of antigenic carbohydrates that are highly expressed 
in various types of cancers conjugated with DTPA and KLH protein, induced a high level of 
antibody titer along with an elevated level of IL-4 in mice. Treatment of tumors with the col-
lected sera from immunized mice decreased the tumor size in nude mice as well. None of the 
immunized mice illustrated any sign of tumor growth after injection of MCF-7 cells compared 
to the control animals. These findings, based on the newly presented structure of the Globo H 
antigen, lend exciting and promising evidence for clinical advancement in the development of 
a therapeutic vaccine in the future.
Keywords: (Globo H)
3
-DTPA-KLH, glycoconjugate vaccines, breast cancer
Introduction
Cancer is the second leading cause of death after heart disease worldwide, and is 
considered a dire threat to human life, with a probability of death in more than 50% 
of cases. Since most cancers show no clinical symptoms at their early stages of devel-
opment, diagnosis is very difficult or impossible until they become metastatic, when 
cure becomes virtually impossible. Therefore, developing a vaccine against cancers 
to produce strong antibodies against small micrometastatic cells could decrease the 
chance of development of the cancer.1,2
The design of therapeutic vaccines for the treatment of cancers is underway in 
many laboratories. These vaccines are intended to shrink tumor cells and prevent their 
regeneration, as well as delay or stop cancer cell growth.3
Normally, the immune system sees the cancer cells as normal cells within the 
body, and does not consider them as dangerous or foreign. Therefore, it does not 
conduct a strong attack against them.4 There are many factors that help cancer 
cells to escape from the immune system. Cancer cells carry the normal self-
antigens that help them to hide, as well as releasing some chemical messages 
that may suppress the activated anticancer immune responses, which allows 
them to escape even after being recognized by the immune system.5 Recent 
studies have indicated that carbohydrates have an obvious and undeniable role 
in causing tumor malignancy. Carbohydrates on the surface of tumor cells are 
usually present as glycoprotein, mussing, and glycosphingolipid.1 Researchers 
have recently discovered the presence of detectable antibodies in the serum 
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of cancer patients. Their findings indicated a probable 
immunity and immune response against the cancerous 
factors and eventually cancer.6 In recent years, many 
experiments have been conducted for the production and 
evaluation of anticancer glycoconjugate vaccines, and 
many achievements have been accomplished.7 It appears 
that the production of an effective treatment vaccine is 
even more difficult than developing a cancer-preventive 
vaccine.8
It has been suggested that the ideal time for the 
immune system to respond against cancer cells could 
be the time immediately after the surgery and chemo-
therapy period, when the anticancer vaccine can train the 
immune system in order to identify and kill the remains 
of cancerous cells.6 If sufficient antibody titer is produced 
against antigens to omit tumor cells from the blood and 
lymphatic system and to kill micrometastatic cells, a 
noticeable change will appear in the curing methods of 
cancer patients.
Several preclinical studies have been performed to 
investigate the production of antibodies against carbo-
hydrate antigens on the surface of tumor cells in order to 
reduce tumor severity.10,11 A number of clinical experi-
ments have shown that prescribing monoclonal antibodies 
is clinically efficient.12,13 Naturally released antibodies 
against antigens on cell surfaces, especially carbohy-
drate antigens, have had a close relationship with the 
development of new cancer therapies at different clinical 
stages.14–16 So far, various studies have demonstrated that 
immunization against polysaccharide glycoconjugates 
is effective, while immunizing against polysaccharides 
alone is not.17–19
These findings indicate that polysaccharides could induce 
immunity, but need to be conjugated in order to be recognized 
by the immune system and provide immunity. Immunization 
with polyribosylribitol phosphate (PRP) induces immunity 
in children above 2 years old, whereas in children under 
2 years old who are the target population for Haemophilus 
influenzae type B, PRP needs to be conjugated with another 
protein, such as tetanus toxin, for the production of PRP-T 
vaccine.20 Therefore, an effective vaccination against cancers 
probably requires tumor-specific glycoconjugates to provide 
strong immunity against tumor cells and their establishment 
in the body.9
One of the suggested proteins for conjugating polysac-
charides to produce anticancer vaccines is the keyhole 
limpet hemocyanin (KLH) protein.21 KLH is a large, mul-
tisubunit, oxygen-carrying metalloprotein, and is found in 
the hemolymph of the giant keyhole limpet – Megathura 
crenulata.
One of the most recently suggested anticancer vaccines is 
a vaccine against breast cancer, which is the most common 
cancer in women. “Globo” is one of the known polysaccha-
rides on the surface of cancerous breast cells (MCF-7). Globo 
can be conjugated with KLH protein to provide a complex 
that could have an anticancer feature in the humoral immune 
system against breast cancer.22
Zhu et al23 have been able to stimulate the immune 
system to elevate IgG and IgM levels against Globo-KLH 
along with lysis of MCF-7 cells. So far, several derivatives 
of Globo-KLH vaccine have been derived and evaluated. In 
all cases, only a single polysaccharide chain of Globo has 
been used, while the appearance of Globo on the cancer cell 
surface is a triple chain.
The aim of this project was to produce a newer form of 
Globo-KLH containing three sugar residues, similar to what 
appears in nature as a triple chain (Figure 1).
Materials and methods
All animal protocols were reviewed and approved by the 
Pasteur Institute of Iran Animal Care Protocol Review Com-
mittee. All chemicals were purchased from Sigma-Aldrich, 
Canada, unless otherwise stated.
Forty female CB6F1 mice were purchased from the 
Pasteur Institute of Iran Animal Care facility. CB6F1 hybrid 
mice are the F
1
 progeny result of a cross between female 
BALB/c (H-2d) and C57BL/6 (B6; H-2b) mice. Mice were 
divided into five groups of eight, and injected with different 
vaccine regimens.
synthesis of (globo)
3
–diethylenetriamine 
pentaacetic acid–Klh
All substances were used without purification unless noted. 
Solvents were distilled under positive-pressure nitrogen 
stream: tetrahydrofuran (THF) with sodium benzophenone 
ketyl; ether with LiAlH
4
, CH
2
Cl
2
, and toluene; and benzene 
with CaH
2
. All reactions were under N
2
 pressure.
Column chromatography was performed using either 
silica gel 60 (40–63 μm) (Merck, Ottawa, Canada) or H-type 
silica gel (10–40 μm) for the normal phase. For the inverse 
phase, we used LiChroprep RP-18 (12–25 μm) (catalog 
number 113901; EMD Millipore, USA).
synthesis of 3-6-di-O-benzyl-d-glucal
Both D-glucal (8 g, 54.7 mmol) and (Bu
3
Sn)
2
O (30.7 mL, 10 M 
equivalent) were refluxed for 20 hours in dry C
6
H
6
 (150 mL) 
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3
-DTPa-Klh antigen
with a Dean–Stark trap apparatus. The mixture was cooled 
to below boiling point and treated with benzyl bromide 
(BnBr) (21 mL) and tetra-n butylammonium bromide 
(TBABr) (35.3 g). The mixture was refluxed for 17 hours 
and cooled down and dried by evaporation. The residue 
was then diluted by ethyl acetate (EtOAc; 2×20 mL), and 
washed using distilled water (3×300 mL). It was then 
filtered, condensed, and dried by Na
2
So
4
. The column 
chromatography of raw materials was performed using 
15%–20% EtOAc in hexanes, which resulted in the desired 
product (11.66 g, with 65% purity) in the form of a color-
less oily residue.
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Figure 1 suggested chemical structure of a stronger derivation than globo h Klh.
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synthesis of 1,5-anhydro-6-O-(TiPs)- 
2-deoxy-d-lyxo-hex-1-enopyranose
Under a stream of nitrogen (N
2
), 6.1 g triisopropylsilyl 
chloride (TIPSCl; 31.8 mmol), 4.2 g D-glucal (28.8 mmol), 
and 4.3 g imidazole (63.2 mmol) was added to 20 mL 
di methylformamide (DMF) at 0°C and mixed appropriately. 
The mixture was then kept at room temperature and stirred 
for 24 hours, followed by the addition of 250 mL EtOAc 
and 250 mL distilled water. After the separation of layers, 
the blue (aqueous) layer was extracted by the addition of 
more EtOAc (2×250 mL). The organic layer was dried later 
using Na
2
SO
4
, filtered, and concentrated under vacuum 
evaporation. The residue was then purified using column 
chromatography (eluent, 15%–30% EtOAc:hexane) to 
obtain the desired compound in the form of a light-yellow 
viscous solution.
synthesis of 1,5-anhydro-6-O-(TiPs)-
3,4-O-carbonyl-2-deoxy-d-lyxo-hex-1-
enopyranose
The aforementioned solution (2.4 g, 14.8 mmol) was then 
mixed with 2.4 g carbonyldiimidazole (14.8 mmol) in 
40 mL dry THF under N
2
 pressure. Three imidazole crystals 
were then added and the mixture stirred for 30 minutes, 
followed by the addition of 1.2 g carbonyldiimidazole 
(7.4 mmol). The mixture was stirred for 90 more minutes. 
After evaporation of the solvent under vacuum, the residue 
was mixed with 200 mL chloride and 100 mL distilled 
water. After separation of the organic layer, it was washed 
with 100 mL water, filtered, dried, and condensed using 
Na
2
SO
4
 under vacuum. The residue was then purified 
by column chromatography using a 15% EtOAc:hexane 
mixture to obtain the desired compound in the form of a 
clear syrup.
synthesis of lactal carbonate 1
The syrup (22 mg) was mixed with 5 mL methylene chlo-
ride, followed by the addition of 30 mL dimethyldioxirane 
(prepared on the same day, as explained by Robert et al)24 
slowly in drops at 0°C. The mixture was then stirred for 
1 hour at 0°C and analyzed by thin-layer chromatography 
to verify the complete expansion of the compound. Then, 
the mixture was condensed under vacuum and azeotroped 
using 5 mL benzene. Then, 11.6 g of 3-6-di-O-benzyl-D-
glucal solution was added and the mixture azeotroped again 
with 2×5 mL benzene, concentrated under vacuum, and 
dried using 1.5 mL THF under N
2
 pressure. A zinc chloride 
solution (820 μL of a 1 M solution in THF, 0.82 mmol) was 
added slowly in drops and the mixture returned to room 
temperature and kept for 24 hours. The mixture was then 
added to 10 mL NaHCO
3
 (1 M) solution and extracted by 
EtOAc (3×20 mL). The extracted organic compound was 
then filtered, condensed, dried by Na
2
SO
4
, and purified 
by column chromatography (gradient elution, 10%–25% 
EtOAc:hexanes) to obtain the desired compound.
synthesis of lactal carbonate
One milliliter of a 60% solution of NaOH in water was added 
to 30 mL DMF containing 2.7 g of lactal carbonate 1 and 
574 μL BnBr at 0°C, followed by stirring for 5 minutes. The 
mixture was then kept at room temperature and stirred for 
2 hours. The total mixture content was later transferred to 
70 mL cold distilled water, diluted by EtOAc, washed twice 
with 70 mL distilled water and once with 70 mL salt water, 
filtered and dried by Na
2
SO
4
, followed by column chroma-
tography of raw materials using 10%–12% EtOAc in hexanes 
to obtain the desired compound (2.479 g) with purity of 81% 
in the form of a colorless oil (Figure 2).
synthesis of lactal
A lactal carbonate solution of TIPS (5.62 mmol, 4.28 g) 
was treated with 6.75 mL tetra-n-butylammonium fluoride 
(TBAF; 1.0 M equivalent, 1.0 M) solution mixed with 
25 mL THF and 5 mL MeOH. After 6 hours of incubation 
at room temperature, 4 mL more TBAF was added and the 
mixture stirred for an additional 3 hours. The mixture was 
then condensed and subjected to direct chromatography 
using 4:1 EtOAc-hexane solution to obtain 2.20 g triol. The 
remains of the solution contained cyclic carbonate and a 
mixed carbonate mixture that was hydrolyzed in methanol 
using MeONa (1.0 mL, 25 wt% in MeOH) and purified by 
chromatography. The total productivity was 3.02 g (93%). 
The final product was then used directly in the dibenzyla-
tion stage.
synthesis of disaccharide
A mixture containing 2.95 g thioglycol (5.1 mmol), 
1.33 g Bu
2
SnO (1.05 equivalent), and 1.69 mL (Bu
3
Sn)
2
O 
(0.65 equivalent) was refluxed for 5 hours in dry C
6
H
6
 
(50 mL) under N
2
 pressure until all the water was evaporated. 
The mixture was then cooled to under boiling point, treated 
with 2.43 mL BnBr (4.0 molar equivalent) and 3.29 g TBABr 
(2.0 equivalent), and refluxed with 10 mL C
6
H
6
 for 16 hours. 
The mixture was loaded directly on a silica bar and eluted by 
15%–20% EtOAc-hexanes to obtain the desired compound 
(3.48 g) with 91% purity in the form of clear oil.
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synthesis of 3-O-(4-methoxybenzyl)-d-
glucal
A suspension of 3.70 g D-glucal (25.3 mmol) and 6.30 g 
Bu
2
SnO (1.0 equivalent) was refluxed for 5 hours in 
dry C
6
H
6
 (50 mL) under N
2
 pressure until the water was 
evaporated completely. The mixture was cooled down to 
room temperature and treated with 9.1 g p-methoxybenzyl 
chloride (1.1 equivalent) and 9.1 g TBABr (1.1 equivalent, 
OH
OH
O
O
O
O
O TIPS
O
O
O TIPS
TIPS
Imidazol
DMF
TBIBr
BnBr
PhH
ZnCl
2
THF
BnBr
NaH
DMF
(n-Bu
3
Sn)
2
O
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2
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2
,
quanti
3,3′–dimenthyldioxiran
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O
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Figure 2 synthesis of lactal carbonate.
 
D
ru
g 
De
sig
n,
 D
ev
el
op
m
en
t a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
9.
18
4.
66
.1
29
 o
n 
12
-S
ep
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
Drug Design, Development and Therapy 2015:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
222
hajmohammadi et al
9.10 g) and refluxed for 4 hours. The mixture was then 
filtered through a silica bar and eluted with EtOAc:hexanes 
(4:1). Fractions containing product were condensed and 
the residues crystallized in hexane to obtain a white solid 
crystal as product (4.5 g, approximately 70%).
4,6-Di-O-benzyl-3-O-(4-methoxybenzyl)-
d-glucal synthesis
A mixture of 3-O-(4-methoxybenzyl)-D-glucal (8.56 mmol, 
2.28 g) and BnBr (3.68 molar equivalent, 3.75 mL) solu-
tion was prepared and passed through basic alumina treated 
by NaH 60% (4.0 molar equivalent, 1.37 g) in dry DMF 
(30 mL) under N
2
 pressure at 0°C. The mixture was stirred 
for 30 minutes at 0°C and for 1 hour at room temperature. 
The mixture was then poured on ice pieces, diluted by 
100 mL of distilled water, and extracted by EtOAc-hexanes 
(1:1, 3×100 mL). Organic extracts was washed by water 
(2×100 mL) and dried on Na
2
SO
4
. Column chromatography 
of raw materials was performed using 15% EtOAc-hexanes, 
and resulted in obtaining the desired product in the form 
of a clear liquid.
synthesis of the compound containing 
luoride
A mixture of 4,6-di-O-benzyl-3-O-(4-methoxybenzyl)-D-glucal 
(7.7 mmol, 3.20 g) solution in dry CH
2
Cl
2
 (10 mL) was treated 
with dimethyldioxirane (0.09 M, 80 mL) under N
2
 pressure 
at 0°C. The mixture was stirred until the whole glucal was 
expanded using thin-layer chromatography containing 30% 
EtOAc in hexanes. The solution was deazeotroped under 
N
2
 pressure at 0°C. The residue was then dissolved in dry 
THF (30 mL) under N
2
 pressure at 0°C, followed by treat-
ment with 36 mL TBAF (stored over molecular sieves) and 
stirred for 20 hours at room temperature. The dark-brown 
solution was filtered through a silica pad (~4 cm depth) and 
washed with 200 mL EtOAc, followed by washing twice with 
200 mL distilled water, and dried with MgSO
4
. The residue 
was then dissolved in 30% EtOAc in hexanes (50 mL) and 
filtered through a silica bar (10 cm diameter, 4 cm length), and 
washed again with 1 L of the same solvent. The filtrate was 
condensed to obtain fluorohydrine in high purity. The residue 
was then dissolved in dry DMF (30 mL) under N
2
 pressure 
at 0°C, treated with BnBr (1.5 equivalent, 958 μL), filtered 
through basic alumina, and finally was stirred for 30 minutes 
at 0°C followed by 30 minutes’ stirring at room temperature 
with NaOH (1.5 equivalent, 60% dispersion, 322 mg). The 
reaction was stopped after the mixture was poured on 100 g 
of ice, and the mixture was extracted by EtOAc-hexanes 
1:1 (2×150 mL). Column chromatography was performed 
using 10% EtOAc in hexanes, which resulted in obtaining 
2 g (49%) of desired compound in the form of a light-yellow 
liquid (Figure 3).
OH
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O Bn
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Figure 3 Synthesis of luoride.
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Synthesis of the irst trisaccharide 
containing para-methoxybenzyl
The synthesized lactal (1.0 equivalent, 0.791 mmol, 600 mg) 
and fluorosugar (1.5 equivalent, 679 mg) were synthesized 
in ether, condensed, dried in vacuum for 2 hours, treated by 
di-tert-butylpyridine (1.0 equivalent, 177 mL), and dissolved 
in dry ether (8.5 mL) under N
2
 pressure. In a separate 25 mL 
flask, 2 g of 4 Å molecular sieves was added and dried by 
heat under vacuum and cooled to room temperature. Anhy-
drous silver perchlorate (1.0 equivalent, 163 mg) and SnCl
2
 
(1.0 equivalent, 150 mg) was added to molecular sieve. The 
salt mixture was placed in a water bath, and the sugar solu-
tion was added to the salt using a double-tipped needle and 
stirred for 48 hours at room temperature. The mixture was 
diluted by ether and filtered through a pad of silica, followed 
by washing with ether. The filtrate (70 mL) was diluted twice 
with 50 mL sodium bicarbonate solution and dried under 
Na
2
SO
4
. Column chromatography was performed twice using 
20% EtOAc in hexanes to obtain 561 mg trisaccharides with 
a purity of 54%.
Synthesis of the irst trisaccharide 
without para-methoxybenzyl
A para-methoxybenzyl trisaccharide solution containing 
0.428 mg trisaccharide (561 mmol) was treated with 830 μL 
of distilled water and 126 mg 2,3-dichloro-5,6-dicyano-
1,4-benzoquinone (1.3 equivalent) at 0°C and stirred for 
1 hour at 0°C. The mixture was transferred to 50 mL saturated 
sodium bicarbonate solution, extracted by EtOAc (2×50 mL), 
washed with water and saturated sodium bicarbonate solution 
(2×50 mL), dried with Na
2
SO
4
, condensed under vacuum, 
and purified using column chromatography as previously 
described to obtain 437 mg of the desired trisaccharide in the 
form of a colorless oil with 86% purity (Figure 4).
glycal disaccharide synthesis
TIPS galactal carbonate (3.14 mmol, 4.32 g) was dissolved 
in 20 mL of CH
2
Cl
2
 and cooled to 0°C. The mixture was then 
mixed with 219 mL dimethyldioxirane (~3.14 mmol) and 
incubated at 0°C for 20 minutes, followed by condensation 
using a stream of nitrogen. The residue was then treated with 
O Bn
PMB O
PMB O
O Bn
O
O
O
O
O
O
F
O Bn
O Bn
O Bn
O Bn
Bn OBn O
O Bn
O Bn
O
O
O
O
O
O Bn
HO
O Bn
Bn O Bn O
O Bn
O Bn
O Bn
Bn O
AgClO
4
, SnCl
2
, di-tert-butylpyridine,
4Å, molecular sieves, Et
2
O
DDQ
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2
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H
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Bn O
O Bn
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O BnO Bn
O Bn
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O
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Figure 4 synthesis of trisaccharide.
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20 mL C
6
H
6
 and dried by high vacuum power for 30 min-
utes at 0°C. It was then dissolved in 60 mL THF and cooled 
to -78°C, followed by the addition of 3.32 g (10.95 mmol) 
dry TIPS galactal carbonate and 26.3 mL ZnCl
2
 (1.0 M 
in ether). The mixture was kept at room temperature and 
stirred for 24 hours. It was then treated with 40 mL saturated 
NaHCO
3
 and extracted with 500 mL ether. The combined 
organic phase was washed with 300 mL salt water, dried by 
MgSO
4
, and the raw product was purified by column chro-
matography using 20% EtOAc in hexanes. The resulting 
product was 6.20 g white foam.
glycal trisaccharide synthesis
A mixture of disaccharide (4.08 mmol, 2.64 g) and fucosyl 
fluoride (3.77 mmol, 1.64 g) was deazeotroped three times 
by 10 mL C
6
H
6
 and dried by high vacuum power for 1 hour. 
The residue was then dissolved in 20 mL THF and treated 
with 2,6-di-tert-butylpyridine (11.31 mmol, 2.16 g). The 
aforementioned mixture was later added to a flask contain-
ing AgClO
4
 (7.54 mmol, 1.56 g), SnCl
2
 (7.54 mmol, 1.42 g), 
and 4 Å molecular sieves (4.0 g), and stirred for 30 minutes 
at 40°C for 34 hours. After the mixture was treated with 
40 mL saturated solution of NaHCO
3
 at 4°C, the mixture 
was extracted twice with 300 mL EtOAc. The contents of 
the organic layer were then washed with 200 mL salt water 
and dried by MgSO
4
. The residue was then purified using 
column chromatography as stated earlier to obtain 1.93 g of 
47% purified glycal trisaccharide (Figure 5).
synthesis of iodosulfonamide
A mixture of glycal trisaccharide (0.11 mmol, 118 mg) and 
benzenesulfonamide (0.55 mmol, 87 mg) was deazeotroped 
once by C
6
H
6
, dried by high vacuum for 1 hour, and dis-
solved in 5 mL THF, and then 870 mg freshly activated 4 Å 
molecular sieves (provided from 4 hours heating in oven at 
250°C) was added.
I
2
 (0.22 mmol, 57.5 mg) was sterilized by 100 mg 
Ag(sym-coll)
2
 ClO
4
 (0.22 mmol) in 1 mL THF at room 
temperature until the brown color of iodine had disappeared 
and I(sym-coll)
2
 ClO
4
 was obtained. It was then added to the 
flask containing glycal trisaccharide and benzenesulfonamide 
at 5°C. The mixture was stirred for 1 hour at 5°C and cooled 
using 10 mL Na
2
S
2
O
3
 solution. After filtration and extraction 
by EtOAc (80 mL), the organic layer was washed with 20 mL 
deuterium-depleted water, saturated with 20 mL Cu
2
SO
4
, 
dried by MgSO
4
, and purified by column chromatography 
using silica gel (20% EtOAc in hexanes) to obtain 74 mg 
iodosulfonamide as the result.
ethyl-thio-sulfonamide synthesis
Lithium bis(trimethylsylil)amide (1.0 M in THF, 0.81 mL, 
0.81 mmol) was added to 10 mL DMF containing etiolate 
Ethan solution (1.7 mmol, 102 mg) at -42°C. After 5 minutes’ 
stirring, it was added to a flask containing iodosulfonamide 
(0.33 mmol, 448 mg) in 10 mL DMF at -42°C. The mixture 
was then transferred to room temperature and stirred for 
another 3 hours. It was then diluted with 200 mL diethyl 
ether, washed with 10 mL salt water and saturated with 1 N 
NaHCO
3  
2×10 mL and dried by MgSO
4
. The desired product 
was obtained in the form of a white solid (Figure 6).
hexasaccharide synthesis
An acceptor mixture containing trisaccharides (1 equivalent, 
0.077 mmol, 92 mg), thioglycoside (2 equivalent, 198 mg), 
and activated molecular sieve (560 mg) suspended in Et
2
O-
CH
2
Cl
2
 (2:1) under N
2
 flow was stirred at room temperature 
for 10 minutes. The mixture was then cooled to 0°C and 
treated with 52.4 μL methyl triflate (6.0 equivalent). The 
mixture was then stirred for 4 hours at 0°C and for 1.5 hours 
at about 15°C (mild temperature). The reaction was later 
stopped using 10 mL triethylamine. The mixture was then 
washed and filtered through a silica pad using diethyl ether. 
The filtrate (70 mL) was washed again with 2×50 mL satu-
rated NaHCO
3
 solution, dried with Na
2
SO
4
, and purified by 
high-performance liquid chromatography (HPLC) using a 
MICROSORB Semi-prep Si 80-120-C5 column (Bio-Rad, 
California, USA), 17% EtOAc in hexanes, at a flow rate of 15 
mL/minute and optical density of 260 nm to obtain 158 mg 
(85% purity) of the desired product.
synthesis of azide
A mixture of hexasaccharide glycal and freshly activated 4 Å 
molecular sieve were treated with 1mL dimethyldioxirane 
(0.07 M) in 1 mL CH
2
Cl
2
 at 0°C under nitrogen stream, and 
the residue was dried for 20 minutes under high vacuum 
power. Then, an azidohydrin solution was added to epoxide 
through a container in THF (0.8 mL) and cooled to -40°C. 
Then, ZnCl
2
 in Et
2
O (1 M, 25 μL) was added, the mixture 
allowed to cool to room temperature, and then stirred 
for the next 12 hours. Then, the mixture was diluted by 
EtOAc (50 mL), was washed with NaHCO
3
 saturated solu-
tion (2×20 mL) and salt water (10 mL), dried by Na
2
SO
4
, 
and the raw material purified by column chromatography 
(10%–22% EtOAc in hexanes) to provide 31.3 mg of coupled 
product in the form of a clear oil. To the solution of this 
product (0.013 mmol, 31.3 mg), 4-dimethylaminopyridine 
(0.013 mmol, 1.6 mg) and triethylamine (0.0219 mmol, 
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(globo h)
3
-DTPa-Klh antigen
3.0 μL) was added in CH
2
Cl
2
 (1 mL) and Ac
2
O (0.013 mmol, 
1.2 μL) at 0°C. The mixture was allowed to cool to room 
temperature and stirred for 1 hour. After the solvent had been 
evaporated, the residue was diluted by EtOAc (30 mL) and 
was washed with NaHCO
3
 diluted solution (285 mL) and salt 
water and dried by Na
2
SO
4
. Column chromatography (20% 
EtOAc in hexanes) of raw materials provided 30 mg (95%) 
of the desired product (Figure 7).
synthesis of amide
A mixture containing 66 mg azide (0.023 mmol), 66 mg Lind-
lar catalyst, and 23 mg palmitic anhydrate (0.46 mmol) was 
stirred for 24 hours at room temperature under H
2
. The reac-
tion mixture was filtered through a silica pad, washed with 
20 mL EtOAc, and concentrated under vacuum. The residue 
was then purified by HPLC using 20% EtOAc in hexanes at a 
flow rate of 15 mL/minute and detected at 260 nm wavelength 
using an ultraviolet detector. The final product was 64 mg 
colorless oil with 90% purity (Figure 8).
Synthesis of the inal product of (Globo)
3
-
DTPa-Klh
Approximately 1 mmol of KLH (3 g) was mixed with 
2 mmol of S-2-(4-Isothiocyanatobenzyl)-diethylenetriamine 
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
OH
O Bn
O Bn
O Bn
O Bn
O Bn
O Bn
O
O
O
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O
O
O
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O
O
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Figure 5 synthesis of iodosulfonamide.
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pentaacetic acid (p-SCN-Bn-DTPA) in phosphate-buffered 
saline (PBS) and stirred for 24 hours. The mixture was then 
transferred to a dialysis bag for separation of SCN-DTPA-
KLH. The remainder was then added to a mixture containing 
10 mL of dissolved DMF, acetic acid anhydride (C
4
H
6
O
3
), 
and 10 mg pyridine while stirring for 3 hours at 40°C, until 
the formation of anhydrate. Ten milligrams of 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide plus 2 mL triethylamine 
were then added to the mixture, the contents placed on ice 
for 2 hours, and kept at room temperature afterward. The 
synthesized Globo was later dissolved in 10 mL DMF and 
the pH adjusted to 10.5 using 1 normal NaOH. After the addi-
tion of 125 μL of cyanogen bromide solution (0.2 g in 1 mL 
H
2
O) to acetonitrile, the pH was adjusted to 10.5. After 2.5 
minutes’ incubation at room temperature, 5 mL of 0.5 molar 
adipic dihydrazide as well as 5 mL bicarbonate (0.5 molar) 
were added to the mixture and the pH adjusted to 8.5 using 
1 N HCl and kept at 4°C for 24 hours. The activated Globo 
was then added to the anhydrate and stirred for 2 hours. The 
conformation of the final product was later determined using 
1H nuclear magnetic resonance (NMR), Fourier-transform 
infrared, and HPLC techniques.
animal and biological assays
immunization of mice with vaccine regimens
Mice were divided into five groups of eight, and received 
different vaccine regimens in 200 μL via intraperitoneal injec-
tions. Each mouse received the vaccine four times at 2-week 
intervals. Group 1 received (Globo)
3
-DTPA-KLH, group 2 
(Globo)
3
-DTPA-KLH + adjuvant, group 3 was injected with 
DTPA-KLH as negative control, group 4 received DTPA-
KLH + adjuvant, and group 5 was injected with PBS alone.
All animals were monitored for 4 months. All mice 
were bled prior to the beginning of the experiment and 
after each immunization. The blood was collected from 
the saphenous vein in an Eppendorf tube and centrifuged 
at 1,500 rpm for 15 minutes. The sera were collected and 
kept at -20°C until use.
O
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Figure 6 synthesis of ethyl-thio-sulfonamide.
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(globo h)
3
-DTPa-Klh antigen
antibody titration
The level of antibodies in the mice sera was detected using 
enzyme-linked immunosorbent assay (ELISA). The wells of 
a 96-well plate were coated with either 0.25 μg/well of bovine 
serum albumin or Globo-DTPA-albumin conjugate separately 
and incubated overnight. All wells were blocked with 1% skim 
milk for 1 hour at 37°C. A serial dilution of polled sera (1:50, 
1:100, 1:300, 1:900, 1:2,700, and 1:8,100) from each group of 
mice was prepared, added to the wells, and incubated at 37°C 
for 1 hour. The plate was then washed three times with PBS 
containing 0.1% Tween 20. The antibodies were detected using 
a rabbit antimouse antibody conjugated with horseradish per-
oxidase at a concentration of 1:1,000 and incubated for 1 hour 
at 37°C. The plate was then washed three times and 100 μL 
TMB added to each well and incubated for 15 minutes in the 
dark. The reaction was stopped by the addition of 100 μL of 
0.5 M sulfuric acid to each well, and light intensity was read 
at 450 nm wavelength using a Bio-Rad ELISA reader.
cytokine assay
Both IL-4 and IFNγ were detected using ab100710–IL-4 
(IL-4) and ab46081-IFNγ mouse ELISA kits (Abcam, 
Cambridge, MA, USA), respectively, for the detection of 
cytokines in collected sera from immunized mice.
in vivo tumor-preventive effects
To investigate the antitumor effect of the antibodies in the sera 
of immunized mice, tumors were developed in two groups of 
four nude mice (purchased from the Pasteur Institute of Iran), 
and 20×106 MCF-7 cells were injected into the right limb of 
each mouse. After the tumor size reached approximately 1 
cm, 200 μL of the pooled sera from either the vaccinated mice 
or the control group was injected around the tumor site in 
each nude mouse subcutaneously. The tumor size and growth 
were then monitored during the next 4 weeks.
statistical analysis
Results are presented as means ± standard error of mean. 
We used InStat software for analyses of variance, followed 
by the Student–Newman–Keuls post hoc test. Significant 
differences are based on P0.05.
Results
Conirmation of the synthesis of Globo 
h and globo h-protected precursor
1h-nMr (solvent, cDcl
3
)
δ7.67 (2H, d, J =7.2 Hz), 7.35–7.13 (63H, m), 5.65 (1H, d, 
J =9.0 Hz), 5.63–5.57 (1H, m), 5.43 (1H, br s), 5.33–5.27 
(1H, m), 5.11 (2H, t-l1ke, J =4.0 Hz), 4.94–4.90 (2H, m), 
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Figure 7 synthesis of azide.
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4.88–4.79 (4H, m), 4.76–4.73 (2H, m), 4.71–4.64 (5H, 
m), 4.62–4.58 (3H, m), 4.56–4.49 (5H, m), 4.44 (1H, dd, 
J =8.6 and 2.2 Hz), 4.40 (1H, d, J =7.0 Hz), 4.36–4.32 
(2H, m), 4.30–4.11 (9H, m), 4.02–3.88 (7H, m), 3.81–3.65 
(8H, m), 3.60–3.50 (4H, m), 3.45–3.36 (4H, m), 3.34–3.23 
(5H, m), 3.09 (1H, br s), 2.10–1.98 (4H, m), 2.04 (3H, s), 
1.83 (3H, s), 1.51 (2H, m), 1.30–1.23 (49H, m), 1.10–0.97 
(42H, m), 0.88 (6H, t, J =6.9 Hz).
13c-nMr (solvent, cDcl3)
δ172.4, 169.6, 168.5, 153.4, 140.5, 139.3, 139.2, 138.7, 
138.6, 138.5, 138.4, 138.3, 138.20, 138.1, 138.0, 136.8, 
132.3, 128.9, 128.5, 128.3, 128.3, 128.2, 128.1, 127.9, 127.8, 
127.7, 127.6, 127.5, 127.4, 127.3, 127.2, 127.1,127.0, 103.2, 
101.1, 99.0, 98.4, 98.1, 79.4, 79.3, 78.8, 77.4, 76.5, 76.3, 76.0, 
75.8, 75.2, 74.8, 74.8, 74.3, 74.2, 74.1, 73.5, 73.1, 73.0, 72.9, 
72.7, 72.4, 72.3, 72.2, 70.3, 70.2, 69.5, 68.7, 68.3, 68.1, 68.0, 
67.9, 67.7, 61.2, 60.9, 53.6, 53.3, 51.5, 36.8, 32.2, 31.9, 29.6, 
29.5, 29.4, 29.3, 29.2, 25.6, 22.6, 20.9, 20.7, 18.0, 17.9, 17.9, 
17.9, 16.6, 14.0, 11.8 (Figure 9).
globo h (ceramide)
Fourier transform infrared spectroscopy (FTir) data 
(KBr)
3,356.16, 2,920.73, 2,851.92, 1,734.56, 1,652.90, 1,547.93, 
1,466.19, 1,372.94, 1,260.95, 1,075.45, 1,042.58 cm-1.
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Figure 8 synthesis of antigen.
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(globo h)
3
-DTPa-Klh antigen
1h nMr (solvent, DMsO-4/D2O, 10:1)
δ5.54–5.48 (dt, J =6.7, 15.3 Hz, 1H), 5.37–5.31 (dd, J =7.0, 
15.2 Hz, 1H), 4.95 (bs, 1H), 4.81 (d, J =3.7 Hz, 1H), 4.48 (d, 
J =8.4 Hz, 1H), 4.44 (d, J =8.1 Hz, 1H), 4.25 (d, J =7.6 Hz, 
1H), 4.16 (d, J =7.8 Hz, 1H), 4.10–4.04 (m, 2H), 3.98–3.85 
(m, 5H), 3.81–3.72 (m, 6H), 3.68–3.35 (m, 22H), 3.32–3.25 
(2H, m), 3.04–3.02 (t, J =7.9 Hz, 1H), 2.02 (m, 2H), 1.93 
(m, 2H), 1.82 (s, 3H), 1.44 (m, 2H), 1.23 (m, 46H), 1.08 
(d, J =6.4, 3H), 0.84–0.83 (t, J =6.6, 6 H).
13c-nMr (solvent, cD3OD)
δ176.0, 174.5, 135.2, 131.4, 105.5, 105.4, 104.4, 103.9, 
102.8, 101.0, 81.1, 80.4, 80.0, 79.1, 77.9, 76.8, 76.5, 76.4, 
76.2, 75.5, 74.9, 74.7, 73.5, 73.0, 72.6, 72.4, 71.5, 70.6, 70.6, 
70.3, 69.9, 69.7, 69.7, 68.1, 62.6, 62.6, 61.7, 61.6, 54.8, 54.8, 
53.1, 37.4, 33.5, 33.1, 30.9, 30.9, 30.8, 30.8, 30.8, 30.7, 30.7, 
30.6, 30.5, 30.5, 30.4, 27.2, 23.8, 23.7, 16.7, 14.4.
Mass-spectrum data
[M+]=1,532.6, [M+Na]=1,555.8, [M+2H]2+=778.95, 
[M+3H]3+=519.6 (Figure 10; original data in Supplementary 
materials).
(globo h)
n=1,3-p-Bn-scn-DTPa-Klh synthesis conirmation
hPlc procedure
To confirm the attachment of Globo
3
 to the complex of 
DTPA-KLH, we used HPLC (Table 1).
chn analysis
Carbon, hydrogen, and nitrogen analysis showed the total 
mass of each element residue in the complex, as indicated 
in Table 2.
 C% calculation =฀฀(12.0107× carbon numbers/molecular  
 weight [MW] ×100
 H% calculation =฀(1.0079× hydrogen numbers/MW) ×100
 N% calculation =฀(14.0087× nitrogen numbers/MW) ×100
Calculation of C, H and N numbers from KLH-CHN 
analysis obtained the data:
 C:26.73, H:4.12, N:4.35 (reported from CHN analyzer 
instrument).
 KLH MW = ~3,000 KDa
 C-numbers =26.73×3,000,000/1,201.07=~66,765
 H-numbers =4.12×3,000,000/100.79=~122,631
 N-numbers =4.33×3,000,000/1,400.87=~9,268
Calculation of C, H, and N numbers from (Globo)
3
-KLH-
CHN analysis obtained the data:
C:26.79, H:4.13, N:4.33 (reported from CHN analyzer 
instrument).
We knew that in a conjugate, there is an increase in C, H, 
and N numbers as follows, respectively. In other words, we 
expected an increase in CHN numbers as: C =258, H =484, 
and N =22 (new MW = KLH MW +~5.7 kDa).
 C-numbers =26.79×3,005,700/1,201.07=~67,042
 H-numbers =4.13×3,005,700/100.79=~123,162
 N-numbers =4.33×3,005,700/1,400.87=~9,292
 %C-numbers =฀(67,042–66,765/258) ×100–100=7.3%
 %H-numbers =฀(123,162–122,631/484) ×100–100=10.0%
 %N-numbers =฀(9,292–9268/24) ×100=9.0%
The data statistically confirmed the synthesis of our 
conjugates.
1h nMr study
As the original results depict in the Supplementary 
materials, there was a significant sharp peak regarding 
the anomeric hydrogens of Globo H polysaccharide 
O
O
O
O
O
OH3C
O
O
O
O
O
O
O O
O Bn
O Bn O Bn
O Bn
Bn O
Bn O
Bn O
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Figure 9 Protected antigen.
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(4.5–5.5 ppm) in (Globo H)
3
-DTPA-KLH and Globo 
H-KLH with an integral ratio of 3:1, which confirmed the 
presence of 3 M Globo H in the conjugate of (Globo H)
3
-
DTPA-KLH as well.
immunization results
A significant total of IgM and IgG antibodies was observed 
only against (Globo H)
3
-DTPA-KLH and Globo H-KLH 
compared to other groups (Figure 11). There was also a 
significant difference (P0.05) between (Globo H)
3
-DTPA-
KLH and Globo H-KLH. In general (Globo H)
3
-DTPA-KLH 
was found to be more potent than Globo H-KLH.
cytokine assay
IL-4 and IFNγ levels were determined in the collected sera 
after each injection for all groups. Surprisingly, the cytokines 
were only detected in the mouse group that received (Globo 
H)
3
-DTPA-KLH after the third and fourth injections, as listed 
in Table 3 (Figure 12).
Tumor growth
None of the immunized mice showed any sign of cancer after 
the injection of MCF-7 cells compared to the control animals 
(see Supplementary materials).
Discussion
For successful treatment of a tumor or cancer cells, it is ideal 
to find molecular targets that are not present on normal cells. 
Meezan et al25 were among the first to demonstrate the differ-
ences of tumor glycans from normal cells. It appears that the 
glycosylation of sugar residue on cancer cells is structurally 
atypical to that of healthy cells, due to overexpression of 
specific structures and omission of some others.26 Sugar-
residue association with tumors has also been identified 
recently by monoclonal antibodies and mass spectrometry.27 
Association of glycolipids or glycoproteins has also been 
reported on the surface of certain types of cancer cells.28 
The role of surface carbohydrates and its correlation with 
tumor malignancy is not known yet. However, it appears that 
these antigens could activate immune responses. One of the 
carbohydrates associated with tumors was first isolated from 
breast cancer MCF-7 cells and called Globo H by Hakomori7 
and Bremer et al.29 It is now known that Globo H is pres-
ent on many cancer cells, including prostate, ovary, lung, 
Table 1 Mobile phase and conditions for hPlc analysis
Column accucore 150-c18, 2.6 μm,  
100×2.1 mm 16126-102130
Mobile phase A 0.1% formic acid in water
Mobile phase B 0.1% formic acid in acetonitrile
Gradient
Time (minutes) % B
0 5
5 5
45 50
46 95
50 95
51 5
60 5
Flow rate 0.2 ml/min 
Backpressure at starting  
conditions
170 bar
Run time 90 minutes
Injection wash solvent Water +0.1% formic acid
Notes: One peak in the KLH digest pattern was deinitely translocated from 
~24 minutes to 29 minutes in the (globo)
3
-DTPa-Klh digest pattern. There was a 
very clear signal of globo h presence in the Klh structure.
Abbreviation: hPlc, high-performance liquid chromatography.
Table 2 atomic mass for carbon, hydrogen, and nitrogen 
elements
Element Atomic massa
c 12.0107
h 1.0079
n 14.0087
Note: aFrom periodic table.
O
O NHAc
O Ceramide
O
O O
O
O
O
O O O
O H O H
O HO H
O HO HO H
O HH O
H O
H O H O H O
H O
H O H O
O H
Figure 10 The molecular structure of globo-h antigen.
Notes: c:26.79, h:4.13, n:4.33 (reported from chn analyzer instrument).
3.5
O
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4
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 (
n
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)
Dilutions
PBS
(Globo)
1
-KLH
(Globo)
3
-DTPA-KLH
DTPA-KLH
3
2.5
2
1.5
1
0.5
0
1/50 1/100 1/300 1/900 1/2,700 1/8,100
Figure 11 antibody titration.
Abbreviations: PBs, phosphate-buffered saline; DTPa, diethylenetriamine pentaacetic 
acid; OD, optical density.
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(globo h)
3
-DTPa-Klh antigen
pancreatic, gastric, and colon cancers,24 and high levels of 
anti-Globo H antibody can be detected in serum samples of 
breast cancer patients.30,31 These findings indicate that Globo 
H could be used as a potential target in cancer therapy and 
cancer-vaccine development.
In this study, for the first time, a new chemically desig-
nated three-branch structure of Globo H antigen conjugated 
with KLH was synthesized and characterized. The novelty 
of this structure was regarding the triplicate structure of 
Globo H, which is highly similar to the nature of this antigen 
at its binding sites on cancer cells.17 The next advantage of 
the proposed structure is indicated by its polyamine linker 
DTPA, which facilitates its presentation to Globo H-binding 
sites at the cancerous cell surface as well.18,19 Kudryashov 
et al among others, previously reported the preparation of 
Globo H-KLH vaccine.22,24,32 They also investigated the 
immunogenicity of the Globo H-KLH antigen after ozonoly-
sis of the Globo H aglycone that was followed by reductive 
amination with the KLH carrier protein to generate about 
150 carbohydrate units per protein.24
Globo H is a cancer antigen overexpressed in various 
epithelial cancers. It has been suggested that this antigen can 
serve as a target in cancer immunotherapy. While vaccines 
have been developed to elicit antibody responses against 
Globo H, their anticancer efficacies are unsatisfactory, due 
to the low antigenicity of Globo H. There is a need for a new 
vaccine capable of eliciting high levels of immune responses 
targeting Globo H.
In this study, we successfully synthesized a novel three 
branch Globo H antigen conjugated with a DTPA-KLH mol-
ecule. The triplicate Globo H structure allows this antigen to 
perform with the same antigenic effects as the sugar residue 
on tumor cells, and therefore to induce a better immune 
response against cancer cells.
Administration of (Globo H)
3
-DTPA-KLH in mice 
subcutaneously, elevated the level of both IgM and IgG 
antibody titers significantly (Figure 11). In the meantime, 
IL-4 and IFNγ levels were also elevated significantly in the 
sera of vaccinated mice with (Globo H)
3
-DTPA-KLH com-
pared with the control mice (Figure 12). This phenomenon 
was confirmed after immunotherapy of nude mice with the 
sera collected from immunized animals, which prevented 
the growth of tumor cells or reduced the size of tumors that 
were already developed (Figure 13).
Altogether, we concluded that the new synthesized 
(Globo H)
3
-DTPA-KLH could be a promising vaccine for 
treatment of cancers. More studies are required to find the 
best adjuvant to accompany this vaccine to elicit the best 
immune response against cancer cells. For mass spectrom-
etry results and further information related to the structures 
16
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Figure 12 concentration of il-4 and iFnγ in immunized mice.
Abbreviations: iFn, interferon; il, interleukin; PBs, phosphate-buffered saline; DTPa, diethylenetriamine pentaacetic acid.
Table 3 amount of il-4 and iFnγ in the vaccine-administered 
group after third and fourth injections
Vaccine-received group IL-4 (pg/mL) IFNγ (pg/mL)
Blood sampling after  
third injection
1.62145 1.49553
Blood sampling after  
fourth injection
12.8276 18.11630526
Blood sampling from  
control mice
Untraceable Untraceable
Abbreviations: iFn, interferon; il, interleukin.
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of the Globo-H compound, please refer to Supplementary 
Figures S1-S10 at the end of the article.
Disclosure
The authors report no conflicts of interest in this work.
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Figure S1 globo h mass spectroscopy.
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Figure S7 (globo h)
3
-DTPa-Klh hPlc.
Abbreviations: DTPa, diethylenetriamine pentaacetic acid; hPlc, high-performance liquid chromatography.
Figure S8 Klh 1h nMr.
Abbreviations: DMsO, dimethyl sulfoxide; nMr, nuclear magnetic resonance.
1 1H NMR in DMSO at 298 k 91/3/29
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Figure S9 globo h-Klh 1h nMr.
Abbreviations: DMsO, dimethyl sulfoxide; nMr, nuclear magnetic resonance.
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Figure S10 (globo h)
3
-DTPa-Klh 1h nMr.
Abbreviations: DMsO, dimethyl sulfoxide; DTPa, diethylenetriamine pentaacetic acid; nMr, nuclear magnetic resonance.
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(globo h)
3
-DTPa-Klh antigen
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